X
Xiuyan Wang
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 77
Citations - 9822
Xiuyan Wang is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chimeric antigen receptor & T cell. The author has an hindex of 25, co-authored 70 publications receiving 7675 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila,Isabelle Riviere,Xiuyan Wang,Shirley Bartido,Jae H. Park,Kevin J. Curran,Stephen S. Chung,Jolanta Stefanski,Oriana Borquez-Ojeda,Malgorzata Olszewska,Jinrong Qu,Teresa Wasielewska,Qing He,Mitsu Fink,Himaly Shinglot,Maher Youssif,Mark Satter,Yongzeng Wang,James Hosey,Hilda Quintanilla,Elizabeth Halton,Yvette Bernal,Diana C. G. Bouhassira,Maria E. Arcila,Mithat Gonen,Gail J. Roboz,Peter Maslak,Dan Douer,Mark G. Frattini,Sergio Giralt,Michel Sadelain,Renier J. Brentjens +31 more
TL;DR: Diagnostic criteria for a severe cytokine release syndrome (sCRS) is defined and serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS.
Journal ArticleDOI
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens,Marco L. Davila,Isabelle Riviere,Jae H. Park,Xiuyan Wang,Lindsay G. Cowell,Shirley Bartido,Jolanta Stefanski,Clare Taylor,Malgorzata Olszewska,Oriana Borquez-Ojeda,Jinrong Qu,Teresa Wasielewska,Qing He,Yvette Bernal,Ivelise Rijo,Cyrus V. Hedvat,Rachel Kobos,Kevin J. Curran,Peter G. Steinherz,Joseph G. Jurcic,Todd L. Rosenblat,Peter Maslak,Mark G. Frattini,Michel Sadelain +24 more
TL;DR: The results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions, forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT.
Journal ArticleDOI
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park,Isabelle Riviere,Mithat Gonen,Xiuyan Wang,Brigitte Senechal,Kevin J. Curran,Craig S. Sauter,Yongzeng Wang,Bianca Santomasso,Elena Mead,Mikhail Roshal,Peter Maslak,Marco L. Davila,Renier J. Brentjens,Michel Sadelain +14 more
TL;DR: A phase 1 trial involving adults with relapsed B‐cell ALL who received an infusion of autologous T cells expressing the 19‐28z CAR at the Memorial Sloan Kettering Cancer Center found that patients with a low disease burden before treatment had markedly enhanced remission duration and survival and had a markedly lower incidence of the cytokine release syndrome and neurotoxic events after infusion.
Journal ArticleDOI
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens,Isabelle Riviere,Jae H. Park,Marco L. Davila,Xiuyan Wang,Jolanta Stefanski,Clare Taylor,Raymond Yeh,Shirley Bartido,Orianna Borquez-Ojeda,Malgorzata Olszewska,Yvette Bernal,Hollie J. Pegram,Mark Przybylowski,Daniel Hollyman,Yelena Usachenko,Domenick Pirraglia,James Hosey,Elmer Santos,Elizabeth Halton,Peter Maslak,David A. Scheinberg,Joseph G. Jurcic,Mark L. Heaney,Glenn Heller,Mark G. Frattini,Michel Sadelain +26 more
TL;DR: It is concluded that this adoptive T-cell approach is promising and more likely to show clinical benefit in the setting of prior conditioning chemotherapy and low tumor burden or minimal residual disease.
Journal ArticleDOI
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Bianca Santomasso,Jae H. Park,Darin Salloum,Isabelle Riviere,Jessica Flynn,Elena Mead,Elizabeth Halton,Xiuyan Wang,Brigitte Senechal,Terence J. Purdon,Justin R. Cross,Hui Liu,Behroze Vachha,Xi Chen,Lisa M. DeAngelis,Daniel Li,Yvette Bernal,Mithat Gonen,Hans-Guido Wendel,Michel Sadelain,Renier J. Brentjens +20 more
TL;DR: The findings implicate cellular components other than T cells and suggest novel links between systemic inflammation and characteristic neurotoxicity symptoms and identify neurotoxicity risk factors.